NeoGenomics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Anthony P. Zook
- Full Time Employees
- 2,500
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 9490 NeoGenomics Way Fort Myers FL United States 33912
- IPO Date
- Dec 10, 2012
- CIK
- 0001077183
- Website
- neogenomics.com
- Similar Companies
- Business
- NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The company offers an extensive oncology-focused testing menu across multiple modalities, including clinical cancer testing; molecular and next-generation sequencing (NGS) testing; interpretation and consultative services; validation laboratory services; clinical trials and research testing; and oncology data solutions. NeoGenomics serves a broad customer base comprising pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations primarily across the United States and Europe. Its laboratories are CAP accredited and CLIA certified and are located in multiple sites including Fort Myers and Tampa in Florida; California locations such as Aliso Viejo, Carlsbad, and San Diego; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Phoenix, Arizona; and Cambridge, United Kingdom. Founded in 2002 and headquartered in Fort Myers, Florida, NeoGenomics operates as a leader in precision oncology diagnostics offering over 500 advanced tests for personalized cancer care. Recent major developments include the completion of the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey, which expands NeoGenomics' oncology testing reach and service capabilities in the Northeast U.S. The company has also formed a global strategic partnership with Biognosys AG to enhance its proteomics-based product offerings for its Pharma Services division, expanding into next-generation proteomics solutions for drug discovery and clinical trials in oncology drug development. Additionally, NeoGenomics has launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling liquid biopsy test, advancing its position in the precision oncology market by offering less invasive and faster genomic testing options for therapy selection, trial matching, and disease monitoring. NeoGenomics is further strengthening its portfolio with several new next-generation sequencing products in late-stage development, scheduled for launch to bolster its presence in hospitals and community oncology settings. These strategic expansions and product innovations underscore the company's commitment to clinical leadership and sustainable growth in the cancer diagnostics and research market. NeoGenomics reported consolidated revenue of approximately $661 million for 2024, reflecting a 12% increase driven by higher test volumes. NeoGenomics operates within the healthcare diagnostics and research industry, targeting oncology-focused markets with advanced genetic and molecular testing services. It supports oncology clinical care and pharma research globally, with notable operations in the U.S. and the UK, and its strategic initiatives continue to broaden its capabilities in precision medicine and oncology data analytics. The company employs around 2,200 professionals and is led by CEO Anthony P. Zook. Its ongoing commitment to innovation and strategic acquisitions positions it as a prominent player in cancer genetics testing and oncology contract research service provider spaces.
Company News
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
NEO Battery Reports Fiscal Year 2027 Second Quarter Results
What NeoGenomics (NEO) Said on Its Q3 Earnings Call
NeoGenomics Reports Third Quarter 2026 Results
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
What's Going On With NeoGenomics Stock Tuesday?
NeoGenomics (NASDAQ:NEO) Hits New 12-Month High After Analyst Upgrade
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
Omada Health (NASDAQ:OMDA) and NeoGenomics (NASDAQ:NEO) Head-To-Head Contrast
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data